Skip to Main Content

Gilead Sciences (GILD) released top-line trial data for its Yescarta medication that may allow the company to leapfrog over a rival in the marketing battle over CAR-T therapies.

The preliminary results of a randomized Phase 3 trial showed the treatment — which involves extracting white blood cells and genetically modifying them to attack cancer — prevented the return of large B-cell lymphoma better than the standard of care, which includes chemotherapy and a stem cell transplant. The study examined patients whose initial treatment had failed and given Yescarta as a so-called second-line treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment